Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial

BACKGROUND: In the FULFIL trial, once-daily single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) resulted in reduced moderate/severe exacerbation rates and conferred significant improvements in lung function and health status in patients with chronic obstructiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Panettieri Jr, Reynold A, Camargo Jr, Carlos A, Cheema, Tariq, El Bayadi, Sherif G, Fiel, Stanley, Vila, Tania M, Jain, Renu G, Midwinter, Dawn, Thomashow, Byron, Ludwig-Sengpiel, Andrea, Lipson, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443998/
https://www.ncbi.nlm.nih.gov/pubmed/36072608
http://dx.doi.org/10.2147/COPD.S367701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443998/
https://www.ncbi.nlm.nih.gov/pubmed/36072608
http://dx.doi.org/10.2147/COPD.S367701

Ejemplares similares